Aclarion Inc. (Nasdaq: ACON, ACONW) has published a peer-reviewed article in Clinicoeconomics and Outcomes Research, titled “The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates.”
The independent cost-effectiveness analysis concludes that Nociscan is effective and less costly compared to provocative discography. The findings illustrate that Nociscan saves $1,712 per patient and improves surgical success by 10%.
“Chronic low back pain is a complex problem that is complicated to diagnose,” said Dr. Doug Beall, chief of radiology services, clinical radiology of Oklahoma and co-author. “I have a keen interest in advanced diagnostics and clinical decision support tools like Nociscan. The profound conclusions within this important paper will not only benefit surgical intervention, but also my non-surgical colleagues in Pain Management and Interventional Radiology. Our industry needs more evidence showcasing clinical and economic improvements when comparing alternatives, and our paper clearly illustrates the cost-effectiveness of Nociscan compared to provocative discography.”
Ryan Bond, chief strategy officer at Broomfield-based Aclarion, said, “We are pleased with the cost-effectiveness results illustrated in this important paper. We believe the results demonstrating Nociscan’s economic outperformance over provocative discography will be important to our physician customers and their patients, but will also speak clearly to the payer community, who are constantly challenged to reconcile the health outcomes achieved for the dollars they spend, in other words, the value in healthcare.”
Chronic low back pain (cLBP) affects approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan is an evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine, objectively quantifying chemical biomarkers associated with disc pain.
